The facts on Glycidyl methacrylate (GMA)

The facts on Glycidyl methacrylate (GMA)

No estimates of current numbers of exposed workers to Glycidyl methacrylate (2,3-epoxypropyl methacrylate) in the EU are available.
Primarily, work-related exposure to glycidyl methacrylate occurs through inhalation, dermal contact, and oral (hand‑to‑mouth) exposure.
Glycidyl methacrylate has a harmonised classification (CLP classification) as Carcinogen category 1B (presumed human carcinogen).

Where risks occur

Glycidyl methacrylate is mainly used to produce other organic basic chemicals, plastics, resins and synthetic rubber. These materials are used in the manufacturing of packaging, coatings and paints, varnishes, adhesives, dental products and devices, bone repair materials or contact lenses. New uses are being developed in medical imaging and drug delivery.

Workers in polymer manufacturing have the highest risk of exposure to glycidyl methacrylate. High exposure can happen during tasks like sampling, maintenance, filling containers, filtering, testing, and removing waste.
Occupations related to dental practice activities, such as dentists, dental assistants, hygienists, and dental laboratory technicians, can be exposed to Glycidyl methacrylate. Workers involved in the manufacture of medical and dental instruments may also be exposed.

More about the substance

Glycidyl methacrylate is a colourless liquid made by human activity. It is mainly used to make plastics (polymers) and acrylic resins. These materials are used in dental products, materials for bone repair, coatings, and contact lenses. They can also be used in materials that come into contact with food, such as packaging. New uses of these polymers are being developed for medical imaging and for targeted drug delivery.
An EU-wide binding occupational exposure limit value is currently under preparation.

Health risks that may occur

Exposure to glycidyl methacrylate occurs via inhalation, dermal and oral (hand-to-mouth contact) routes.
There is limited evidence of whether glycidyl methacrylate causes cancer in humans. Studies in animals show that long-term exposure to this substance may cause cancer and adverse reproductive and fertility effects. Skin sensitising effects in humans have been described.

What you can do

The best way to reduce risk from glycidyl methacrylate exposure is to replace it with a safer substance or to change the process. If this is not possible, steps must be taken to reduce exposure.

Glycidyl methacrylate is generally manufactured in a closed system under well-controlled conditions with no direct worker contact; this also limits air release and keeps exposure low.

Keep the workplace clean and store materials safely. Check exposure levels regularly to make sure safety measures work. Limit the time workers spend in risky areas and restrict access.

Train workers about the risks and how to work safely with glycidyl methacrylate. They should report any early health problems. Provide good washing facilities and enough time for personal hygiene.

Workers who come into close contact with 2,3‑epoxypropyl methacrylate (glycidyl methacrylate), for example during the preparation of dental and bone composite materials, should use appropriate protective equipment (such as gloves and protective clothing) to prevent skin absorption. Personal protective equipment should only be used as a last resort and only considered temporarily, after the possible technical and organisational solutions have been exhausted.

References: ECHA, RAC

Limit values

EU
A BOELV is under preparation.

Please note that due to transitional periods in the Directive, national OELs might deviate from the BOELV. The overview on national OELs is updated in the 4th quarter every year and may also be the reason for deviation.

 Austria

EU directive
 Belgium
EU directive
Bulgaria
EU directive
Croatia
EU directive
Czech Republic
EU directive
Cyprus
EU directive
Denmark
EU directive
Estonia
EU directive
Finland
EU directive
France
EU directive
Germany
EU directive
Greece
EU directive
Hungary
EU directive
Iceland
EU directive
Ireland
EU directive
Italy
EU directive
Latvia
EU directive
Lithuania
EU directive
Luxembourg
EU directive
Malta
EU directive
Netherlands
EU directive
North Macedonia
EU directive
Norway
EU directive
Poland
0,3mg/m³ (TWA), 0,6mg/m³ (STEL)
Portugal
EU directive
Romania
EU directive
Serbia
EU directive
Slovakia
EU directive
 Slovenia
EU directive
Spain
EU directive
Sweden
EU directive
Turkey
EU directive

References: cancer.gov, EFSA, IARC, EC, NIOSH, OSHA, CAREX

Please be aware that for this carcinogen you need to be more cautious when determining potential skin contact and how to regard dermal exposure in your risk reduction strategy.
ECHA registration
CAS number 106-91-2
EC number 203-441-9
Annex VI of CLP 1B
Number of registrations 32
Tonnage band registred 1.000 to 10.000 tonnes per annum

The European Chemicals Agency (ECHA) works for the safe use of chemicals. It implements the EU’s groundbreaking chemicals legislation, benefiting human health, the environment and innovation and competitiveness in Europe.

GESTIS Database

The data pool may be used for the purpose of occupational health and safety or to obtain information on the hazards posed by chemical substances.

General facts

Facts about cancer-causing agents:

  • The direct costs of carcinogen exposure at work across Europe are estimated at 2.4 billion Euros per year.
  • Every year, about 120.000 persons get cancer from exposure to carcinogens at work
  • Annually more than 100.000 people die because of work-related cancer.

Table of contents

Sign up for our newsletter to become part of our community. Or follow us on LinkedIn and join the conversation!